HADES modernizes aerial military intelligence globalsecurity.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalsecurity.org Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
NEW YORK, March 9, 2021 /PRNewswire/ Patients previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may produce levels of antibodies against COVID-19 after a one dose of the Pfizer Inc./BioNTech SE messenger RNA (mRNA) vaccine that are equal to or higher than people not previously infected have after two doses, a new study finds.
Presented virtually March 9 at the Conference for Retroviruses and Opportunistic Infections (CROI), the results of the small, exploratory study also suggest that the immune responses in most patients previously infected with the pandemic virus did not improve further after a second vaccination.